This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pincus, S. H. Articles by Portis, J. Search for Related Content PubMed PubMed Citation Articles by Pincus, S. H. Articles by Portis, J.

 Previous Article  |  Next Article 

J. Virol., Nov 1995, 7152-7158, Vol 69, No. 11
Copyright © 1995, American Society for Microbiology

Protective efficacy of nonneutralizing monoclonal antibodies in acute infection with murine leukemia virus

SH Pincus, R Cole, R Ireland, F McAtee, R Fujisawa and J Portis
Laboratory of Microbial Structure and Function, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, Hamilton, Montana 59840, USA.

We have used an experimental retrovirus infection to study the roles played by different antibodies in resistance to both infection and disease. A molecularly cloned chimeric murine leukemia virus was used to induce acute lethal neurological disease in neonatal mice. A panel of monoclonal antibodies directed against the Gag and Env proteins was tested for protective efficacy. In vitro neutralization assays demonstrated that anti-Env antibodies gave different degrees of neutralization, while no anti-Gag neutralized the virus. In vivo experimental endpoints were onset of clinical signs and premoribund condition. As expected, different anti-Env antibodies demonstrated different degrees of protection which correlated with their neutralizing abilities. Surprisingly, anti-Gag antibodies directed against both p15 (MA protein) and p30 (CA protein) were also protective, significantly delaying the onset of disease. No protection was seen with either of two control antibodies. The protection with anti-Gag was dose related and time dependent and was also produced with Fab fragments. Treatment with anti-Gag did not prevent viremia but resulted in a slight slowing in viremia kinetics and decreased levels of virus in the central nervous systems of mice protected from disease. These data indicate that nonneutralizing antiretroviral antibodies can influence the outcome of retroviral disease. The data also suggest a functional role for cell surface expression of Gag proteins on murine leukemia virus-infected cells.

This article has been cited by other articles:

• Gros, L., Pelegrin, M., Michaud, H.-A., Bianco, S., Hernandez, J., Jacquet, C., Piechaczyk, M. (2008). Endogenous Cytotoxic T-Cell Response Contributes to the Long-Term Antiretroviral Protection Induced by a Short Period of Antibody-Based Immunotherapy of Neonatally Infected Mice. J. Virol. 82: 1339-1349 [Abstract] [Full Text]  
• Gros, L., Dreja, H., Fiser, A. L., Plays, M., Pelegrin, M., Piechaczyk, M. (2005). Induction of Long-Term Protective Antiviral Endogenous Immune Response by Short Neutralizing Monoclonal Antibody Treatment. J. Virol. 79: 6272-6280 [Abstract] [Full Text]  
• Sugahara, D., Tsuji-Kawahara, S., Miyazawa, M. (2004). Identification of a Protective CD4+ T-Cell Epitope in p15gag of Friend Murine Leukemia Virus and Role of the MA Protein Targeting the Plasma Membrane in Immunogenicity. J. Virol. 78: 6322-6334 [Abstract] [Full Text]  
• Dreja, H., Gros, L., Villard, S., Bachrach, E., Oates, A., Granier, C., Chardes, T., Mani, J.-C., Piechaczyk, M., Pelegrin, M. (2003). Monoclonal Antibody 667 Recognizes the Variable Region A Motif of the Ecotropic Retrovirus CasBrE Envelope Glycoprotein and Inhibits Env Binding to the Viral Receptor. J. Virol. 77: 10984-10993 [Abstract] [Full Text]  
• Ourmanov, I., Bilska, M., Hirsch, V. M., Montefiori, D. C. (2000). Recombinant Modified Vaccinia Virus Ankara Expressing the Surface gp120 of Simian Immunodeficiency Virus (SIV) Primes for a Rapid Neutralizing Antibody Response to SIV Infection in Macaques. J. Virol. 74: 2960-2965 [Abstract] [Full Text]  
• Mascola, J. R., Lewis, M. G., Stiegler, G., Harris, D., VanCott, T. C., Hayes, D., Louder, M. K., Brown, C. R., Sapan, C. V., Frankel, S. S., Lu, Y., Robb, M. L., Katinger, H., Birx, D. L. (1999). Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies. J. Virol. 73: 4009-4018 [Abstract] [Full Text]  
• Mazzetti, P., Giannecchini, S., Del Mauro, D., Matteucci, D., Portincasa, P., Merico, A., Chezzi, C., Bendinelli, M. (1999). AIDS Vaccination Studies Using an Ex Vivo Feline Immunodeficiency Virus Model: Detailed Analysis of the Humoral Immune Response to a Protective Vaccine. J. Virol. 73: 1-10 [Abstract] [Full Text]  
• del Mauro, D., Matteucci, D., Giannecchini, S., Maggi, F., Pistello, M., Bendinelli, M. (1998). Autologous and Heterologous Neutralization Analyses of Primary Feline Immunodeficiency Virus Isolates. J. Virol. 72: 2199-2207 [Abstract] [Full Text]